close read more

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Press contact : – presse@servier.com

Press release

Press release
Servier is launching, with the endorsement of the International Society of Hypertension, the third edition of “Because I say so” a public campaign to raise awareness of the importance of blood pressure measurement
Press release
Servier together with World Heart Federation and Global Heart Hub, launches “Use Heart to Act Now on Angina,” a public campaign to raise awareness on angina
Press release
Mediator Trial – Les Laboratoires Servier acknowledge the appeal by the Paris Prosecutor’s Office in the Mediator case
Press release
Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business
Press release
Servier obtains Top Employer Europe 2021 certification
Press release
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
Press release
Financial Year 2019/2020 – Financial results and R&D strategy and pipeline
Press release
Servier appoints Pascal Lemaire as Executive Vice President Finance
Press release
Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases